
## Sarabjot Pabla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6102724/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Visceral Obesity in Non-Small Cell Lung Cancer. Cancers, 2022, 14, 3450.	1.7	1
2	Immune profiling and immunotherapeutic targets in pancreatic cancer. Annals of Translational Medicine, 2021, 9, 119-119.	0.7	15
3	Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response. Biomarker Research, 2021, 9, 56.	2.8	14
4	Visceral Obesity Promotes Lung Cancer Progression—Toward Resolution of the Obesity Paradox in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1333-1348.	0.5	27
5	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology, 2021, 32, 1626-1636.	0.6	86
6	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC. JTO Clinical and Research Reports, 2021, 2, 100254.	0.6	3
7	A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS ONE, 2021, 16, e0260089.	1.1	13
8	Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma. Journal of Personalized Medicine, 2021, 11, 1324.	1.1	0
9	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncolmmunology, 2020, 9, 1773200.	2.1	10
10	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
11	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
12	Body Mass Index Influences the Salutary Effects ofÂMetformin on Survival After Lobectomy for Stage I NSCLC. Journal of Thoracic Oncology, 2019, 14, 2181-2187.	0.5	23
13	Identification of targets for prostate cancer immunotherapy. Prostate, 2019, 79, 498-505.	1.2	25
14	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. Journal of Molecular Diagnostics, 2018, 20, 95-109.	1.2	50
15	Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein. International Journal of Molecular Sciences, 2018, 19, 577.	1.8	13
16	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
17	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. Oncolmmunology, 2018, 7, e1460298.	2.1	14
18	Comprehensive immune and mutational profile of melanoma Journal of Clinical Oncology, 2018, 36, 182-182.	0.8	1

SARABJOT PABLA

#	Article	IF	CITATIONS
19	Immune deserts: Correlation of low CD8 gene expression with non-response to checkpoint inhibition Journal of Clinical Oncology, 2018, 36, 23-23.	0.8	1
20	Effect of CTLA-4 overexpression on response to ipilimumab in melanoma Journal of Clinical Oncology, 2018, 36, 190-190.	0.8	1
21	Long-amplicon TCRÎ <sup>2</sup> repertoire sequencing to reveal human T-cell receptor variable gene polymorphism: Implications for the prediction and interpretation of immunotherapy outcome Journal of Clinical Oncology, 2018, 36, 129-129.	0.8	Ο
22	Correlation of lung cancer mutational profile with immune profile Journal of Clinical Oncology, 2018, 36, 146-146.	0.8	1
23	Combination immunotherapy selection for non-PD-1 axis driven tumors Journal of Clinical Oncology, 2018, 36, e15058-e15058.	0.8	0
24	Combination immunotherapy selection for PD-1 axis driven tumors Journal of Clinical Oncology, 2018, 36, e15024-e15024.	0.8	0
25	Validation of a prognostic 53-immune-gene panel in stage II/III melanoma Journal of Clinical Oncology, 2018, 36, 9576-9576.	0.8	Ο
26	Abstract 2267: A novel method for classification of microsatellite instability (MSI) using the Oncomine Tumor Mutation Load assay. , 2018, , .		0
27	Abstract 5070: Chemokine expression signatures in infiltrated vs non-infiltrated tumors. , 2018, , .		0
28	Abstract 4526: Predicting response: PD-L1 biomarker testing by IHC and RNA-seq. Cancer Research, 2018, 78, 4526-4526.	0.4	1
29	Abstract 4668: Evidence for antigen-driven TCRB chain convergence in the tumor infiltrating T cell repertoire of 85 research subjects with melanoma. , 2018, , .		1
30	Abstract 3679: PD-L1 driven excluded phenotype in melanoma. , 2018, , .		0
31	Algorithmic prediction of response to checkpoint inhibitors: Hyperprogressors versus responders Journal of Clinical Oncology, 2017, 35, 11565-11565.	0.8	3
32	Abstract 620: Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient. , 2017, , .		0
33	Abstract 1625: NCS reveals specimen characteristics have minimal impact on immune gene expression signature. , 2017, , .		0
34	Abstract 1626: Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification. , 2017, , .		0